Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS
Contenido archivado el 2024-06-18

Training Network for the Development of Bacterial ExoPolysaccharides for the treatment of Inflammatory Conditions

Objetivo

The essence of this proposal is to establish a collaborative training network which will develop novel immune-regulatory molecules from Bifidobacterium infantis 35624, for treatment of inflammatory diseases. A multidisciplinary team of four prestigious European partners has been assembled (SME & Coordinator - Alimentary Health Ltd (expert in developing probiotic products); Swiss Institute for Asthma and Allergy Research, (expert in immune-regulation); Vienna Institute of Biotechnology at Universität für Bodenkultur (expert in glycobiology); and University College Cork, Alimentary Pharmabiotics Centre and Department of Microbiology (expert in bioinformatics and glycobiology assembly in probiotic bacteria). Each partner will provide unique critical expertise, through knowledge, personnel and facilities which will be complementary and additive and will provide the synergistic expertise required to successfully deliver on the goal of this project and forge a long-lasting relationship. The end result: a unique opportunity for cross-sector state-of-the-art knowledge transfer and dissemination, through the identification of molecules from B. infantis 35624 with proven efficacy in the treatment of IBS and other inflammatory conditions – expected to have major commercialization, economic and health implications.
B. infantis 35624 is a commensal micro-organism, originally isolated from human gastrointestinal tissue, which has demonstrated unique properties in human clinical studies. B. infantis 35624 consumption is associated with significant improvement in the composite score for abdominal pain/discomfort, bloating/distention, and/or bowel movement difficulty compared with placebo in two appropriately designed studies. No other bacterial strain has shown significant improvement in Irritable Bowel Syndrome (IBS) symptoms. The exact mechanisms underpinning the clinical benefit are not known but modulation of the host immune response is strongly believed to play a role.

Ámbito científico (EuroSciVoc)

Programa(s)

Tema(s)

Convocatoria de propuestas

FP7-PEOPLE-2011-IAPP
Consulte otros proyectos de esta convocatoria

Régimen de financiación

MC-IAPP - Industry-Academia Partnerships and Pathways (IAPP)

Coordinador

SCHWEIZERISCHES FORSCHUNGSINSTITUT FUER HOCHGEBIRGSKLIMA UND MEDIZIN IN DAVOS
Aportación de la UE
€ 270 026,00
Dirección
OBERE STRASSE 22
7270 Davos Platz
Suiza
Región
Schweiz/Suisse/Svizzera Ostschweiz Graubünden / Grigioni / Grischun
Tipo de actividad
Research Organisations
Enlaces
Coste total
Sin datos

Participantes (4)